Ascentage Pharma Group International (HK:6855) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ascentage Pharma Group International has appointed Dr. Marc E. Lippman as an independent non-executive director, starting January 2, 2025. Dr. Lippman, a renowned oncologist and professor at Georgetown University, brings extensive experience in breast cancer research and corporate governance. His addition to the board is expected to enhance the company’s strategic direction amidst its business expansion.
For further insights into HK:6855 stock, check out TipRanks’ Stock Analysis page.